[ad_1]
The US Food and Drug Administration (FDA) today approved "Mavenclad" tablets containing the active ingredient "cladribine" to treat the recurrence of multiple sclerosis in adults, including progressive secondary disease. active.
Mavenclad is generally recommended for patients suffering from non-response to other drugs for the treatment of multiple sclerosis.
"We are committed to supporting the development of safe and effective therapies for multiple sclerosis patients, and the approval of Mavenclad is an additional option for patients who have tried another treatment without success," he said. Billy Dunn, director of neuroscience at the FDA's Drug and Drug Evaluation Center. .
Multiple sclerosis is known to be a chronic disease caused by an autoimmune disease of the central nervous system, which disrupts communication between the brain and other parts of the body.
The effectiveness of Mavenclad has been demonstrated in a clinical trial involving 1,366 patients with relapsing multiple sclerosis, which has significantly reduced the number of relapses experienced by these patients compared to placebo, as well as the development of 39; disability.
One of the major side effects of Mavenclad is that it can increase the risk of malignancies and fetal damage and should not be used in patients with tumors.
The drug should not be used in pregnant women because of the possible risks to the fetus.
Other warnings: low number of lymphocytes (white blood cells), may increase the risk of inflammation, sepsis, bone marrow suppression, upper respiratory tract infections, headaches and low numbers of lymphocytes.
This is the detail of the FDA's approval of a new multiple sclerosis drug for non-responders to today's treatments. Thank you for letting us know by giving you all the details and all the necessary information.
It should also be noted that the original news was published and published on the beauty magazine and that the editorial team of Gulf 365 has confirmed that it may have been changed and that 39, it had been fully transferred or quoted. You can read and follow the news of this news from its source.
[ad_2]
Source link
